| Timothy S. Hart, Md, Psc | |
|
933 29th St Ashland KY 41101-3021 | |
| (606) 325-7500 | |
| (606) 326-9136 |
| Full Name | Timothy S. Hart, Md, Psc |
|---|---|
| Speciality | Clinic/Center |
| Location | 933 29th St, Ashland, Kentucky |
| Authorized Official Name and Position | Karen A. Hart (NURSE PRACTITIONER) |
| Authorized Official Contact | 6063257500 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Timothy S. Hart, Md, Psc 933 29th St Ashland KY 41101-3021 Ph: (606) 325-7500 | Timothy S. Hart, Md, Psc 933 29th St Ashland KY 41101-3021 Ph: (606) 325-7500 |
| NPI Number | 1518254747 |
|---|---|
| Provider Enumeration Date | 07/08/2011 |
| Last Update Date | 07/08/2011 |
| Medicare PECOS PAC ID | 6305019605 |
|---|---|
| Medicare Enrollment ID | O20111102000270 |
News Archive
LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.
Although schizophrenia is increasingly understood as a neurodevelopmental disorder, environmental factors are known to play an important role in the disease onset and progression.
New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.
University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases.
Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518254747 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | 3007005 (Kentucky) | Primary |
| Provider Name | Timothy Hart |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174668420 PECOS PAC ID: 9234210675 Enrollment ID: I20080111000307 |
News Archive
LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.
Although schizophrenia is increasingly understood as a neurodevelopmental disorder, environmental factors are known to play an important role in the disease onset and progression.
New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.
University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases.
Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.
› Verified 3 days ago
| Provider Name | Karen A Hart |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972890101 PECOS PAC ID: 2264605567 Enrollment ID: I20120419000560 |
News Archive
LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.
Although schizophrenia is increasingly understood as a neurodevelopmental disorder, environmental factors are known to play an important role in the disease onset and progression.
New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.
University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases.
Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.
› Verified 3 days ago
| Provider Name | Tiffany Malloy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528549706 PECOS PAC ID: 0941554141 Enrollment ID: I20181106002268 |
News Archive
LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.
Although schizophrenia is increasingly understood as a neurodevelopmental disorder, environmental factors are known to play an important role in the disease onset and progression.
New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.
University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases.
Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.
› Verified 3 days ago
News Archive
LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.
Although schizophrenia is increasingly understood as a neurodevelopmental disorder, environmental factors are known to play an important role in the disease onset and progression.
New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.
University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases.
Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.
› Verified 3 days ago
Ovp Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2550 Carter Ave, Ashland, KY 41101 Phone: 304-429-1088 | |
George Carl Borst Iii Psc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1201 St.christopher Drive, Ashland, KY 41101 Phone: 606-324-1101 Fax: 606-324-0404 | |
Hazel Yang, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2025 Carter Ave, Ashland, KY 41101 Phone: 606-325-1894 Fax: 606-325-9193 | |
Malcolm H. King, Psc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2301 Lexington Ave, Suite 205, Ashland, KY 41101 Phone: 606-325-9633 Fax: 606-325-9634 | |
Bellefonte Pediatrics, Ashland Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2910 Carter Ave, Ashland, KY 41101 Phone: 606-326-9001 Fax: 606-326-9005 | |
Kings Daughters - Boyd County High School Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14375 Lions Ln, Ashland, KY 41102 Phone: 606-408-8920 Fax: 606-408-8908 | |
Eric F. Smith, Do Psc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 617 23rd St, Suite 130, Ashland, KY 41101 Phone: 606-329-2888 Fax: 606-329-2890 |